Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration
 Pursuant to 21 CFR 1301.33(a), this is notice that on July 6, 2004, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed: 
                    ( print page 61044) Drug
ScheduleCathinone (1235)
IMethcathinone (1237)
IN-Ethylamphetamine (1475)
IN,N-Dimethylamphetamine (1480)
IAminorex (1585)
I4-Methylaminorex (cis isomer) (1590)
IGamma hydroxybutyric acid (2010)
IMethaqualone (2565)
IAlpha-Ethyltryptamine (7249)
ILysergic acid diethylamide (7315)
ITetrahydrocannabinols (7370)
IMescaline (7381)
I3,4,5-Trimethoxyamphetamine (7390)
I4-Bromo-2,5-dimethoxyamphetamine (7391)
I4-Bromo-2,5-dimethoxyphenethylamine (7392)
I4-Methyl-2,5-dimethoxyamphetamine (7395)
I2,5-Dimethoxyamphetamine (7396)
I2,5-Dimethoxy-4-ethylamphetamine (7399)
I3,4-Methylenedioxyamphetamine (7400)
I5-Methoxy-3,4-methylenedioxyamphetamine (7401)
IN-Hydroxy-3,4-methylendioxyamphetamine (7402)
I3,4-Methylendioxy-N-ethylamphetamine (7404)
I3,4-Methylenedioxymetham- phetamine (7405)
I4-Methoxyamphetamine (7411)
IBufotenine (7433)
IDiethyltryptamine (7434)
IDimethyltryptamine (7435)
IPsilocybin (7437)
IPsilocyn (7438)
IAcetyldihydrocodeine (9051)
IBenzylmorphine (9052)
ICodeine-N-oxide (9053)
IDihydromorphine (9145)
IHeroin (9200)
IHydromorphinol (9301)
IMethyldihydromorphine (9304)
IMorphine-N-oxide (9307)
INormorphine (9313)
IPholcodine (9314)
IAcetylmethadol (9601)
IAllylprodine (9602)
IAlphacetylmethadol except levo-alphacetylmethadol (9603)
IAlphameprodine (9604)
IAlphamethadol (9605)
IBetacetylmethadol (9607)
IBetameprodine (9608)
IBetamethadol (9609)
IBetaprodine (9611)
IHydroxypethidine (9627)
INoracymethadol (9633)
INorlevorphanol (9634)
INormethadone (9635)
ITrimeperidine (9646)
IPhenomorphan (9647)
IPara-Fluorofentanyl (9812)
I3-Methylfentanyl (9813)
IAlpha-Methylfentanyl (9814)
IAcetyl-alpha-methylfentanyl (9815)
IBeta-hydroxyfentanyl (9830)
IBeta-hydroxy-3-methylfentanyl (9831)
IAlpha-Methylthiofentanyl (9832)
I3-Methylthiofentanyl (9833)
IThiofentanyl (9835)
IAmphetamine (1100)
IIMethamphetamine (1105)
IIPhenmetrazine (1631)
IIMethylphenidate (1724)
IIAmbobarbital (2125)
IIPentobarbital (2270)
IISecobarbital (2315)
IIGlutethimide (2550)
IINabilone (7379)
II1-Phenylcyclohexylamine (7460)
IIPhencyclidine (7471)
II1-Piperidinocyclohexane- carbonitrile (8603)
IIAlphaprodine (9010)
IICocaine (9041)
IICodeine (9050)
IIDihydrocodeine (9120)
IIOxycodone (9143)
IIHydromorphone (9150)
IIDiphenoxylate (9170)
IIBenzoylecgonine (9180)
IIEthylmorphine (9190)
IIHydrocodone (9193)
IILevomethorphan (9210)
IILevorphanol (9220)
IIIsomethadone (9226)
IIMeperidine (9230)
IIMethadone (9250)
IIMethadone-intermediate (9254)
IIDextropropoxyphene, bulk (non-dosage forms) (9273)
IIMorphine (9300)
IIThebaine (9333)
IILevo-alphacetylmethadol (9648)
IIOxymorphone (9652)
IINoroxymorphone (9668)
IIRacemethorphan (9732)
IIAlfentanil (9737)
IISufentanil (9740)
IIFentanyl (9801)
II
 The company plans to manufacture small quantities of the listed controlled substances to make reference standards for distribution to their customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA 
                    **Federal Register**
                     Representative (CCD) and must be filed no later than December 13, 2004. Dated: September 28, 2004. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.


[FR Doc. 04-23053 Filed 10-13-04; 8:45 am] BILLING CODE 4410-09-P